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1607-551X/Copyright ª 2015, KaohsiuAbstract We evaluated the relationship between prostatic resistive index (RI) and cardiovas-
cular system (CVS) risk factors in patients with benign prostatic hyperplasia. The study
included 120 patients who were attending our outpatient clinic with lower urinary tract symp-
toms related to benign prostatic hyperplasia. The clinical, laboratory, anthropometric data,
and CVS risk factors (hypertension, diabetes mellitus, metabolic syndrome, history of CVS
events, and smoking) of the patients were evaluated regarding the association between pros-
tate RI level by regression analyses. The prostatic RI levels of the patients were measured using
power Doppler imaging. In univariate regression analysis, there were statistically significant re-
lationships between prostatic RI levels and the patients’ age, International Prostate Symptom
Score, hip circumference, fasting blood glucose, prostate specific antigen, triglycerides, high-
density lipoprotein cholesterol, low-density lipoprotein cholesterol, total prostate volume, ur-
oflowmetric maximal flow rate, and all investigated CVS risk factors (p < 0.05). The prostatic
RI levels were found to be associated with fasting blood glucose and total prostate volume, and
also with CVS risk factors including only metabolic syndrome and cigarette smoking in the
multivariate regression analysis. Our results showed that prostatic RI level is significantly
related to metabolic syndrome and smoking among the investigated CVS risk factors.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
itim ve Arastirma Hastanesi, Uroloji Klinigi, Ulku Mahallesi, Talatpasa Boulevard, Number 5, Ankara
ail.com (B.K. Aktas).
4.12.008
ng Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
Vascular risk factors and resistive index 195Introduction
Benign prostatic hyperplasia (BPH) is histologically defined
as a nonmalignant, unregulated overgrowth of the prostate
gland. Secondary to an enlarged prostate, BPH may be
clinically associated with lower urinary tract symptoms
(LUTS) [1]. LUTS in the aging man is primarily caused by BPH.
Up to 90% of men in their 70s have some LUTS suggestive of
BPH (LUTS/BPH), and their health-related quality of life is
impaired because of these discomfiting symptoms [2]. LUTS/
BPH may less commonly progress to serious morbidities
including acute urinary retention, a need for surgery, uri-
nary incontinence, or a recurrent urinary tract infection [3].
Age and genetics play important roles in the etiologies of
BPH and LUTS. And, in addition to them, unhealthy diets, a
sedentary lifestyle, inflammation, and some major cardio-
vascular system (CVS) risk factors including hypertension
(HT), noninsulin-dependent diabetes mellitus (DM), obesity,
smoking, dyslipidemia, and metabolic syndrome (MetS)
were reported to be novel modifiable risk factors in the
development of BPH in recent studies [4e8].
Transrectal ultrasonography is one of the classical
methods used in the evaluation of BPH patients. The use of
transrectal probes in color and power Doppler imaging (PDI)
gives detailed information about intraprostatic vascularity
[9]. It has been reported that the development of LUTS/
BPH causes an increase in both vascular resistance and
prostatic resistive index (RI), and prostatic RI is correlated
with the symptom score and urine flow rate in LUTS/BPH
patients [10,11]. In this study, with an attempt to provide
etiologic information and find new preventions, we evalu-
ated the relationship between the prostatic RI levels and
CVS risk factors in patients with LUTS/BPH.
Methods
Patients
A total of 120 consecutive BPH patients aged 50 years or
older and exhibiting LUTS at our urology outpatient clinic in
a tertiary care teaching hospital between January 2013 and
March 2014 were prospectively included in this study. Pa-
tients with a history of prostatic malignancy, prostatic
surgery, bladder neck or urethral stricture, and previous
LUTS therapy, and those with neurologic diseases affecting
the lower urinary tract were not included in the study. The
patients were fully informed about the study design, and
informed consent was obtained from all participating
patients.
Initially, a detailed medical history was taken from each
patient. CVS risk factors including smoking status, presence
of DM, HT, or a history of CVS events (coronary heart dis-
ease or myocardial infarction) were recorded. The urologic
evaluation included a digital rectal examination, Interna-
tional Prostatic Symptom Score (IPSS), urinalysis, maximum
flow rate (Qmax) on uroflowmetry, and postvoid residual
urine volume. Anthropometric measurements including
weight, height, hip circumference (HC), and waist circum-
ference (WC) were taken for each patient by the same
observer (S.T.), using the same methods and instruments
for all the patients, and body mass index values werecalculated by dividing weight in kilograms by height in
meters squared. WC and HC were measured respectively by
using a nonelastic constant tension tape at the midpoint of
the lowest rib and iliac crest at the end of exhalation, and
around the widest portion of the buttocks with the partic-
ipant standing. Their blood pressure was measured using a
Braun BP6200 Exactfit 5 Automatic Blood Pressure Monitor
(Kaz Inc., Braun GmbH, Kronberg, Germany). The blood
samples were drawn from the overnight-fasting partici-
pants, and the serum levels of fasting blood glucose (FBG),
triglyceride (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and
prostate-specific antigen (PSA) were recorded. The criteria
proposed for the clinical diagnosis of MetS were provided by
the report of the National Cholesterol Education Program’s
Third Adult Treatment Panel III, any three of the five
following factors: abdominal obesity (WC >102 cm), HT
(blood pressure >130/85 mmHg or taking antihypertensive
medication), hyperglycemia (FBG >110 mg/dL), hyper-
triglyceridemia (serum TG >150 mg/dL), and reduced
levels of HDL-C (<40 mg/dL) [12].
Measurement of prostatic RIs
The prostatic RIs were measured by a radiologist (T.D.)
using PDI. The ultrasound examination consisted of a
transrectal ultrasonography and PDI using a GE Logiq E9
(General Electric Healthcare Systems, Chalfont St Giles,
UK) with a 9-MHz endocavitary probe while the patient was
lying on top of an examination table in a left lateral de-
cubitus position. The patients were asked to empty their
urinary bladder to prevent intraprostatic vasculature from
the compression. The total prostate volume (Vp) and tran-
sitional zone volumes (Vtz) were calculated using the
ellipsoid formula, and then recorded. The blood flow from
the three capsular arteries on the largest transverse section
of the prostate was measured, and then a spectral wave-
form analyses was performed. When the pulsatile wave-
forms of a given Doppler spectrum became stable, the RIs
[(maximum velocity  minimum velocity)/maximum ve-
locity] were measured from each of the three blood flow
samples using the onboard software, and the mean value
was calculated and then recorded.
Statistical analysis
All statistical analyses were performed using SPSS, version
18 (SPSS Inc., Chicago, IL, USA). The descriptive statistics
were presented as mean  SD, and statistical analyses were
performed using Pearson’s correlation and linear regression
tests. A p value < 0.05 was considered significant. Addi-
tionally, we conducted a post hoc power analysis with the
G*Power 3.0.10 software program (Heinrich-Heine Univer-
sity, Du¨sseldorf, Germany) to identify the power achieved
[13].
Results
The mean values of patient characteristics are shown in
Table 1. Of the total 120 patients, 60 (50.0%) were hyper-
tensive, 49 (40.8%) were diabetic, 58 (48.3%) had MetS, 55
Table 2 Correlation among PRI, patient characteristics
and CVS risk factors.
Variables PRI
r p R2
Age (y) 0.408 < 0.001 0.167
Height (cm) 0.166 0.070 0.028
Weight (kg) 0.095 0.303 0.009
BMI (kg/m2) 0.019 0.841 0.000
WC (cm) 0.130 0.156 0.017
HC (cm) 0.248 0.006 0.062
FBG (mg/dL) 0.512 < 0.001 0.263
TG (mg/dL) 0.221 0.016 0.049
LDL-C (mg/dL) 0.427 < 0.001 0.182
HDL-C (mg/dL) 0.309 0.001 0.096
IPSS 0.453 < 0.001 0.205
PSA (ng/mL) 0.466 < 0.001 0.217
Vp (mL) 0.528 < 0.001 0.279
Vtz (mL) 0.397 < 0.001 0.157
Qmax (mL/sn) 0.399 < 0.001 0.159
PVR urine volume (mL) 0.084 0.372 0.007
HT 0.553 < 0.001 0.306
DM 0.627 < 0.001 0.393
CVS events history 0.579 < 0.001 0.335
MetS 0.620 < 0.001 0.385
Smoking 0.286 0.002 0.082
BMI Z body mass index; CVS Z cardiovascular system;
DMZ diabetes mellitus; FBGZ fasting blood glucose; HCZ hip
circumference; HDL-C Z high-density lipoprotein cholesterol;
HT Z hypertension; IPSS Z international Prostatic Symptom
Score; LDL-C Z low-density lipoprotein cholesterol;
MetS Z metabolic syndrome; PRI Z prostatic resistive index;
PSA Z prostate-specific antigen; PVR Z postvoid residual;
Qmax Z maximum flow rate on uroflowmetry;
TG Z triglyceride; Vp Z total prostate volume;
Vtz Z transitional zone volume; WC Z waist circumference.
Table 1 Mean patient characteristics.
Variables Mean  SD
Age (y) 62.1  8.6
Height (cm) 169.6  5.12
Weight (kg) 77.3  11.04
BMI (kg/m2) 26.9  3.4
WC (cm) 103.5  12.11
HC (cm) 102.5  6.7
FBG (mg/dL) 107.3  25.8
TG (mg/dL) 148.4  39.1
LDL-C (mg/dL) 137.1  27.4
HDL-C (mg/dL) 41.8  8.2
IPSS 20.5  6.6
PSA (ng/mL) 2.8  4.0
Vp (mL) 46.8  33.4
Vtz (mL) 11.3  10.7
Qmax (mL/sn) 11.4  5.1
PVR urine volume (mL) 100.7  96.1
PRI 0.74  0.068
BMIZ body mass index; FBGZ fasting blood glucose; HCZ hip
circumference; HDL-C Z high-density lipoprotein cholesterol;
IPSS Z international Prostatic Symptom Score; LDL-C Z low-
density lipoprotein cholesterol; PRIZ prostatic resistive index;
PSA Z prostate-specific antigen; PVR Z postvoid residual;
Qmax Z maximum flow rate on uroflowmetry; SD Z standard
deviation; TG Z triglyceride; Vp Z total prostate volume;
Vtz Z transitional zone volume; WC Z waist circumference.
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smokers. There were 46 hypertensives (76.4%), 44 diabetics
(89.8%), 44 patients with a history of CVS events (80.0%),
and 47 patients with MetS (81.0%) who were identified as
smokers. Prostatic RI levels were positively correlated with
age, IPSS, PSA, FBG, TG, LDL-C, Vp, and Vtz, and negatively
correlated with HC, HDL-C, and Qmax. Prostatic RI levels
were also positively correlated with CVS risk factors
including HT, DM, MetS, smoking, and history of CVS events
(Table 2).
In the univariate regression analysis, there were statis-
tically significant relationships between the prostatic RI
levels and age, IPSS, HC, FBG, PSA, TG, HDL-C, LDL-C, Vp
and Vtz, Qmax, and all investigated CVS risk factors (Tables 3
and 4). However, in the multivariate regression analysis,
the prostatic RI levels were found to be related to FBG, Vp,
and the CVS risk factors including only MetS and smoking
(Tables 3 and 4).
The power of the present study to detect a medium
effect size (0.3) was calculated to be 99.3%; critical
tZ 1.98; dfZ 118; noncentrality parameter dZ 3.44 at a
significance level of 0.05 (two-tailed test) using correlation
analysis.Discussion
The availability of power and color Dopplers on transrectal
probes improved the diagnosis of BPH via the detection of
intraprostatic vascularity [14]. PDI, the next generation of
color Doppler imaging, is based on the detection of signal
amplitude, which determines the density of red blood cells,the independent flow rate, and direction [15]. The devel-
opment of BPH was reported to increase vascular resistance
and prostatic RI [16,17]. In the present study, prostatic RI
was found to correlate positively with both Vp and IPSS, and
negatively with Qmax, which is similar to previous studies
[18,19]. It is not clear how prostatic RI increases in BPH, but
it is considered that the growing hypertrophic prostate
pushes the capsule outward and results in an increase of
intraprostatic pressure and prostatic RI [20]. The decreases
in both intraprostatic pressure and prostatic RI following
transurethral prostatectomy in the patients with LUTS/BPH
corroborate with this hypothesis [21].
The two well-known etiologic factors of LUTS/BPH are
aging and testicular androgens [4]. However, in some
studies, a relationship between the development of LUTS/
BPH and CVS risk factors such as HT, obesity, dyslipidemia,
DM, and MetS has been reported [5e8]. Several studies have
suggested that CVS risk factors may cause enlargement of
the prostate by causing chronic prostatic ischemia [22,23].
Using cell culture models, Berger et al. [24] detected that
prostatic stromal cells increase the secretion of growth
factors in response to hypoxia. However, Takada et al. [25]
reported that CVS risk factors that cause arteriosclerosis
are not related to prostatic RI in patients with symptomatic
Table 3 Results of univariate and multivariate regression analyses of PRI according to patient characteristics.
Variables Univariate analysis Multivariate analysis
Constant Beta t p Beta t p
Constant 1.461 1.035 0.303
Age (y) 0.539 0.003 12.582 < 0.001 0.001 1.238 0.219
Height (cm) 1.119 0.002 1.830 0.070 0.004 0.527 0.599
Weight (kg) 0.790 0.001 1.034 0.303 0.004 0.440 0.661
BMI (kg/m2) 0.755 0.000 0.201 0.841 0.012 0.475 0.636
WC (cm) 0.670 0.001 1.428 0.156 0.001 1.133 0.260
HC (cm) 1.004 0.003 2.786 0.006 0.002 1.813 0.073
FBG (mg/dL) 0.600 0.001 6.483 < 0.001 0.001 3.491 0.001
TG (mg/dL) 0.688 0.000 2.456 0.016 0.000 0.768 0.444
LDL-C (mg/dL) 0.600 0.001 5.123 < 0.001 0.000 1.837 0.069
HDL-C (mg/dL) 0.852 0.003 3.535 0.001 0.000 0.298 0.766
IPSS 0.649 0.005 5.520 < 0.001 0.001 1.563 0.121
PSA (ng/mL) 0.723 0.008 5.719 < 0.001 0.002 0.731 0.466
Vp (mL) 0.695 0.001 6.758 < 0.001 0.001 2.231 0.028
Vtz (mL) 0.717 0.003 4.696 < 0.001 0.001 0.616 0.539
Qmax (mL/sn) 0.799 0.005 4.651 < 0.001 0.001 0.665 0.507
PVR urine volume (mL) 0.735 0.000 0.897 0.372 0.000 0.503 0.616
R Z 0.727 F Z 6.936
R2 Z 0.529 p < 0.001
Adjusted R2 Z 0.452
BMI Z body mass index; FBG Z fasting blood glucose; HC Z hip circumference; HDL-C Z high-density lipoprotein cholesterol;
IPSS Z international prostatic symptom score; LDL-C Z low-density lipoprotein cholesterol; PRI Z prostatic resistive index;
PSAZ prostate-specific antigen; PVRZ postvoid residual; QmaxZ maximum flow rate on uroflowmetry; TGZ triglyceride; VpZ total
prostate volume; Vtz Z transitional zone volume; WC Z waist circumference.
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among CVS risk factors causing arteriosclerosis. Chen et al.
[23] found a significant relationship between prostatic RI
and the number of vascular risk factors including obesity,
HT, DM, hyperlipidemia, and CVS events in patients with
BPH, but this time, MetS was not counted as a CVS risk
factor in the study.
In the present study, the prostatic RI level was found to
be significantly associated with only MetS and smoking
among the CVS risk factors investigated in patients with
LUTS/BPH, and indeed, 81% of our patients with MetS were
smokers. A significant relationship between MetS and LUTS/
BPH has also been shown in a few other studies [6,26,27].
Hammarsten et al. [28] found that Vp and the annualTable 4 Results of univariate and multivariate regression analy
Variables Univariate analysis
Constant Beta t p
HT 0.708 0.075 7.215 < 0.00
DM 0.710 0.086 8.743 < 0.00
CVS events history 0.709 0.079 7.710 < 0.00
MetS 0.705 0.084 8.589 < 0.00
Smoking 0.710 0.046 3.245 0.00
CVS Z cardiovascular system; DM Z diabetes mellitus; HT Z hypertprostate growth rate were higher in patients with MetS than
in the control group. A significant relationship between
MetS and prostatic RI in patients with BPH may be explained
by an increased Vp in patients with MetS. The significant
relationship between prostatic RI, MetS, and Vp found in
patients with LUTS/BPH in our study also supports this
theory.
One might think that HT and DM rates of the present
study seem higher than those in daily urologic practice.
However, our data are consistent with previously published
results that belong to a population of the same age group in
our country [29]. Despite their high prevalence rates, HT
and DM were not found to be associated with prostatic RI in
our cohort.ses of PRI according to CVS risk factors.
Multivariate analysis
Beta t p
Constant 0.685 60.794 < 0.001
1 0.017 0.945 0.347
1 0.018 1.056 0.293
1 0.028 1.757 0.082
1 0.035 1.935 0.045
2 0.024 2.026 0.045
R Z 0.717 F Z 16.962
R2 Z 0.515 p < 0.001
Adjusted R2 Z 0.484
ension; MetS Z metabolic syndrome.
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observational studies, unmeasured confounders such as
other nutritional or lifestyle factors might have potentially
affected our results. The relatively small sample size and
the lack of a control group are also limitations to our study.
Therefore, controlled future studies with a large number of
patients are needed to support our findings.Conclusion
Our results showed that among CVS risk factors, MetS and
smoking were related to prostatic RI in patients with LUTS/
BPH. Chronic prostatic ischemia related to CVS risk factors
might, therefore, play an important role in the pathogen-
esis of LUTS/BPH.References
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